Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-045 in Moderate-to-Severe Atopic Dermatitis
NCT07011706Phase 2Active, not recruiting
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- IgG Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bosakitug in atopic dermatitis (AD), sponsored by Aclaris Therapeutics, Inc.. Started May 2025; status: active, not recruiting.
02
Drugs
bosakitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07011706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011706.